肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2012年
8期
550-552
,共3页
张英兰%石红梅%范凝芳%冯宇娇%康艳
張英蘭%石紅梅%範凝芳%馮宇嬌%康豔
장영란%석홍매%범응방%풍우교%강염
结直肠肿瘤%同型半胱氨酸%循环酶法
結直腸腫瘤%同型半胱氨痠%循環酶法
결직장종류%동형반광안산%순배매법
Colorectal neoplasms%Homocysteine%Enzymatic circling assay
目的 探讨结直肠癌患者治疗前后血清同型半胱氨酸( Hcy)水平的变化,为临床疗效观察及预后评估提供依据.方法 采用循环酶法测定50例对照组和58例结直肠癌患者治疗前后血清Hcy水平,并随访12个月,观察其变化,分析其与疗效及预后的关系.结果 结直肠癌组Hcy水平明显高于对照组[( 16.90±5.35) μmol/L比(10.23±3.06) μmol/L](P＜0.01);并与TNM分期相关,Ⅲ～Ⅳ期患者Hcy水平明显高于Ⅰ～Ⅱ期[(18.49±5.13 ) μmol/L比(15.20±4.86) μmol/L](P＜0.05).治疗结束时Hcy水平与治疗前相比显著下降[(13.39±4.98)μmol/L比(16.90±5.35)μmol/L](P＜0.01),且治疗后3个月Hcy水平[(10.23±3.17) μmol/L]明显低于治疗结束时(P＜0.05).手术后12个月内复发组血清Hcy水平明显高于未复发组[(17.18±4.82) μmol/L比(12.36±3.19) μmol/L](P＜ 0.01).结论 血清Hcy水平对结直肠癌疗效观察及预后判断有一定参考价值.
目的 探討結直腸癌患者治療前後血清同型半胱氨痠( Hcy)水平的變化,為臨床療效觀察及預後評估提供依據.方法 採用循環酶法測定50例對照組和58例結直腸癌患者治療前後血清Hcy水平,併隨訪12箇月,觀察其變化,分析其與療效及預後的關繫.結果 結直腸癌組Hcy水平明顯高于對照組[( 16.90±5.35) μmol/L比(10.23±3.06) μmol/L](P＜0.01);併與TNM分期相關,Ⅲ～Ⅳ期患者Hcy水平明顯高于Ⅰ～Ⅱ期[(18.49±5.13 ) μmol/L比(15.20±4.86) μmol/L](P＜0.05).治療結束時Hcy水平與治療前相比顯著下降[(13.39±4.98)μmol/L比(16.90±5.35)μmol/L](P＜0.01),且治療後3箇月Hcy水平[(10.23±3.17) μmol/L]明顯低于治療結束時(P＜0.05).手術後12箇月內複髮組血清Hcy水平明顯高于未複髮組[(17.18±4.82) μmol/L比(12.36±3.19) μmol/L](P＜ 0.01).結論 血清Hcy水平對結直腸癌療效觀察及預後判斷有一定參攷價值.
목적 탐토결직장암환자치료전후혈청동형반광안산( Hcy)수평적변화,위림상료효관찰급예후평고제공의거.방법 채용순배매법측정50례대조조화58례결직장암환자치료전후혈청Hcy수평,병수방12개월,관찰기변화,분석기여료효급예후적관계.결과 결직장암조Hcy수평명현고우대조조[( 16.90±5.35) μmol/L비(10.23±3.06) μmol/L](P＜0.01);병여TNM분기상관,Ⅲ～Ⅳ기환자Hcy수평명현고우Ⅰ～Ⅱ기[(18.49±5.13 ) μmol/L비(15.20±4.86) μmol/L](P＜0.05).치료결속시Hcy수평여치료전상비현저하강[(13.39±4.98)μmol/L비(16.90±5.35)μmol/L](P＜0.01),차치료후3개월Hcy수평[(10.23±3.17) μmol/L]명현저우치료결속시(P＜0.05).수술후12개월내복발조혈청Hcy수평명현고우미복발조[(17.18±4.82) μmol/L비(12.36±3.19) μmol/L](P＜ 0.01).결론 혈청Hcy수평대결직장암료효관찰급예후판단유일정삼고개치.
Objective To investigate the changes of serum homocysteine (Hcy) level before and after treatment in patients with colorectal cancer,and provide the reference for clinical therapeutic efficacy and prognosis.Methods Enzymatic circling assay was used to measure the serum Hcy levels in 50 controls and 58 patients with colorectal cancer before and after treatment with a.follow-up of 12 months.The changes of Hcy aud the relationship between Hcy and therapeutic efficacy or prognosis were analyzed.Results Scrum Hcy level in patients with colorectal cancer was significantly higher than that in controls [(16.90±5.35) μmol/L vs (10.23±3.06) μmol/L] (P ＜ 0.01),and it was closely associated with TNM stage.Serum Hcy level in patients of stage Ⅲ-Ⅳ was significantly higher than that of stage Ⅰ-Ⅱ [(18.49±5.13) μmol/L vs (15.20±4.86) μmol/L] (P ＜ 0.05).The Hcy level in patients at the end of treatment was significantly lower than that before treatment [(13.39±4.98) μmol/L vs (16.90±5.35) μmol/L] (P ＜ 0.01),and the Hcy level after the treatment for 3 month was significantly lower than that at the end of treatment [(10.23±3.17) μmol/L] (P ＜ 0.05).The Hcy level in patients with recurrence during 12 months after operation was significantly higher than that without recurrence [(17.18±4.82) μmol/L vs (12.36±3.19) μmol/L] (P ＜ 0.01).Conclusion Serum level of Hcy might be a useful marker for predicting therapeutic efficacy and prognosis in patients with colorectal cancer.
